Regulatory Affairs

Drug Importation is Coming, Trump Said

In other countries, drug prices can be 50 to 60 percent lower in some cases for “the exact same pill, from the exact same factory, from the exact same company,” despite the U.S. footing the research and development bills, Trump said. Read More

Impax Draws Wide Support in FTC Dispute Over Opana ER Settlement

Generic drugmakers, antitrust economists and a public-interest law firm that defends free enterprise all supported Impax in amicus briefs filed in a federal appeals court, arguing that the Federal Trade Commission erred in its ruling that Impax’s 2010 settlement with Endo Pharmaceuticals was anticompetitive. Read More